← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA569.7x15.3x20.7x
EV / LTM revenue941.6x2.6x5.4x
Premium to unaffected price13627%41%63%
Premium to 30-day VWAP3032%47%63%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
015302010: 11 deals, 2 clean on every measure2010112011: 15 deals, 6 clean on every measure2011152012: 19 deals, 9 clean on every measure2012192013: 18 deals, 10 clean on every measure2013182014: 16 deals, 9 clean on every measure2014162015: 14 deals, 10 clean on every measure2015142016: 9 deals, 7 clean on every measure201692017: 13 deals, 11 clean on every measure2017132018: 17 deals, 6 clean on every measure2018172019: 14 deals, 4 clean on every measure2019142020: 15 deals, 5 clean on every measure2020152021: 18 deals, 9 clean on every measure2021182022: 23 deals, 13 clean on every measure2022232023: 30 deals, 13 clean on every measure2023302024: 18 deals, 10 clean on every measure2024182025: 26 deals, 15 clean on every measure2025262026: 18 deals, 9 clean on every measure202618
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 17.4x median across 43 dealsHealthcare17.4xn=43Materials: 9.7x median across 13 dealsMaterials9.7xn=13
Deals by sector
Healthcare: 252 dealsHealthcare252Materials: 42 dealsMaterials42
Deals by buyer type
Financial sponsor: 8 dealsFinancial sponsor8Strategic: 176 dealsStrategic176Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 109 dealsUnclassified109
Deals by enterprise value
Under $250m: 123 dealsUnder $250m123$250m to $1bn: 46 deals$250m to $1bn46$1bn to $5bn: 72 deals$1bn to $5bn72$5bn to $20bn: 43 deals$5bn to $20bn43Over $20bn: 8 dealsOver $20bn8Not computed: 2 dealsNot computed2
Deals by industry code
Business Services & Software: 471 dealsBusiness Services & Sof…471Chemicals, Pharmaceuticals & Allied Products: 294 dealsChemicals, Pharmaceutic…294Depository Institutions: 289 dealsDepository Institutions289Electronics & Electrical Equipment: 185 dealsElectronics & Electrica…185Holding & Other Investment Offices: 174 dealsHolding & Other Investm…174Instruments, Medical Devices & Optical Goods: 147 dealsInstruments, Medical De…147Oil & Gas Extraction: 124 dealsOil & Gas Extraction124Electric, Gas & Sanitary Services: 119 dealsElectric, Gas & Sanitar…119Communications: 109 dealsCommunications109Insurance Carriers: 106 dealsInsurance Carriers106
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Baxalta Inc
2016-01-11 · Public merger · $18.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Shire Pharmaceuticals International
Strategic
Healthcare$16bnn.a.2.7x
38%
DEFM14A
Includes stock
Horizon Therapeutics Public Ltd Co
2015-10-15 (filed) · Public merger · $46.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$7.5bn54.9x12.2x
40%
DEFM14A
Includes stock
WuXi PharmaTech (Cayman) Inc.
2015-08-14 · Take-private · $5.75 a share
Not named in the filing
Unclassified
Healthcare$2.8bn18.8xn.a.
n.a.
SC 13E3
All cash
East Dubuque Nitrogen Partners, L.P.
2015-08-09 · Public merger · $2.57 a share
Not named in the filing
Unclassified
Materials$406mn.a.1.2x
n.a.
14% to VWAP
DEFM14A
All cash
Cytec Industries Inc/de/
2015-07-28 · Public merger · $75.25 a share
Not named in the filing
Unclassified
Healthcare$6.0bn21.6xn.a.
29%
DEFM14A
All cash
Mylan II B.V.
2015-07-28 (filed) · Public merger · $75.00 a share
Not named in the filing
Unclassified
Healthcare$44bn21.5x5.3x
n.a.
DEFM14A
All cash
Kythera Biopharmaceuticals Inc
2015-06-17 · Public merger · $75.00 a share
Not named in the filing
Unclassified
Healthcare$1.8bnn.a.n.a.
26%
DEFM14A
All cash
Pozen Inc /Nc
2015-06-08 · Public merger · $7.20 a share
Not named in the filing
Unclassified
Healthcare$189mn.a.11.5x
33%
DEFM14A
All cash
Pozen Inc /Nc
2015-06-08 · Public merger · $7.20 a share
Not named in the filing
Unclassified
Healthcare$189mn.a.11.5x
n.a.
DEFM14A
All cash
Midatech Pharma US Inc.
2015-06-03 · Public merger · $0.27 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Shareholder Representative Services, LLC
Strategic
Healthcare-$5mn.a.-1.9x
n.a.
DEFM14A
Includes stock
Zep Inc.
2015-04-07 · Public merger · $20.05 a share
Not named in the filing
Unclassified
Materials$673m12.3x1.0x
n.a.
DEFM14A
All cash
Polypore International, Inc.
2015-02-23 · Public merger · $60.50 a share
Asahi Kasei
Strategic
Healthcare$3.2bn22.6xn.a.
n.a.
DEFM14A
All cash
Hospira Inc
2015-02-05 · Public merger · $90.00 a share
Not named in the filing
Unclassified
Healthcare$16bn22.3xn.a.
42%
DEFM14A
All cash
Tobira Therapeutics, Inc.
2015-01-14 · Public merger · $14.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Regado Biosciences, Inc.
Strategic
Healthcare$453mn.a.n.a.
n.a.
DEFM14A
Includes stock
Arbutus Biopharma Corp
2015-01-11 · Public merger · $0.61 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
OnCore Biopharma, Inc.
Strategic
Healthcare-$99mn.a.-6.6x
n.a.
DEFM14A
Includes stock
Auxilium Pharmaceuticals Inc
2014-11-17 · Public merger · $33.25 a share
QLT Holding Corp.
Strategic
Healthcare$1.9bnn.a.n.a.
n.a.
DEFM14A
All cash
Cadista Holdings Inc.
2014-11-17 (filed) · Take-private · $1.60 a share
Not named in the filing
Unclassified
Healthcare$173mn.a.1.6x
n.a.
SC 13E3
All cash
Allergan Inc
2014-11-16 · Public merger · $129.22 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Actavis plc
Strategic
Healthcare$36bn17.1x5.1x
19%
DEFM14A
Includes stock
Cadista Holdings Inc.
2014-11-13 (filed) · Take-private · $1.60 a share
Not named in the filing
Unclassified
Healthcare$173mn.a.1.6x
n.a.
SC 13E3
All cash
Rockwood Holdings, Inc.
2014-10-01 (filed) · Public merger · $50.65 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Albemarle Corporation
Strategic
Materials$4.2bn13.9x3.0x
n.a.
DEFM14A
Includes stock
Liposcience Inc
2014-09-24 · Public merger · $5.25 a share
Laboratory Corporation of America Holdings
Strategic
Healthcare$53mn.a.n.a.
65%
DEFM14A
All cash
TAMINCO Corp
2014-09-11 · Public merger · $26.00 a share
Eastman Chemical Company
Strategic
Materials$2.7bnn.a.n.a.
9%
DEFM14C
All cash
Corgenix Medical Corp/Co
2014-08-27 · Public merger · $0.27 a share
Centennial Medical Holdings, Inc.
Strategic
Healthcare$12m17.4x1.1x
n.a.
DEFM14A
All cash
PetroLogistics LP
2014-05-27 · Public merger · $14.00 a share
GP Holdings
Strategic
Healthcare$2.3bn9.7x3.0x
n.a.
DEFM14C
All cash
Furiex Pharmaceuticals, Inc.
2014-04-27 · Public merger · $95.00 a share
Forest Laboratories, Inc.
Strategic
Healthcare$1.0bnn.a.27.0x
19%
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More